RTI-336 as a Treatment for Methamphetamine Dependence

Status Withdrawn

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of RTI-336 as a treatment for methamphetamine (METH) dependence in non-treatment-seeking METH-dependent volunteers.

Clinical Trial Description

Methamphetamine (METH) is a highly addictive stimulant and acute exposure causes dopamine (DA) release and stimulates midbrain reward centers. The proposed work represents an important research effort with considerable public health significance in that it will evaluate a compound targeted specifically at DA transporter (DAT) inhibition for the treatment of METH dependence. The knowledge gained may ultimately support development and implementation of evidence-based treatments for METH dependence, a drug abuse problem with tremendous public health impact.

One therapeutic strategy is to develop and test compounds that normalize (increase) DA to determine if treatment with these drugs reduces METH use. A similar approach has been proposed as a treatment for cocaine dependence (Howell and Wilcox 2001; Mello and Negus 1996), another disorder associated with abnormally low DA activity (Martinez et al. 2007). In an effort to identify a DAT selective inhibitor, a number of 3-phenyltropane analogs were synthesized by RTI International. Among these, preclinical studies have shown that RTI-336 produced cocaine-like discriminative stimulus effects and reduced cocaine self-administration in rats, and produced dose-dependent suppression of cocaine self-administration in rhesus monkeys.

RTI-336 recently received IND-approval (75,778) for preliminary safety testing in healthy male volunteers, and is scheduled to be completed by February 2009. Subsequent to this effort, RTI-336 will be evaluated in a phase I trial involving cocaine-dependent volunteers. The current application puts forth, for the first time, a proposal to evaluate the preliminary efficacy of this very promising candidate medication in non-treatment-seeking METH-dependent volunteers. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01601717
Study type	Interventional
Source	Baylor College of Medicine
Contact
Status	Withdrawn
Phase	Phase 1
Start date	January 2010
Completion date	January 2012

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04070521` - EEG Monitoring in the Emergency Department
Completed	`NCT00729391` - Women-Focused HIV Prevention in the Western Cape	Phase 2/Phase 3
Active, not recruiting	`NCT03129334` - Preventing Prescription Drug Abuse in Middle School Students	N/A
Completed	`NCT02733003` - Implementation Research for Vulnerable Women in South Africa	N/A
Completed	`NCT02573948` - Feasibility of Interventions on People Who Inject Drugs in Vietnam
Completed	`NCT02282306` - Phone Interview to Prevent Recurring Opioid Overdoses	N/A
Withdrawn	`NCT01847300` - cSBI-M for Young Military Personnel	N/A
Withdrawn	`NCT01523444` - Advancing Adolescent Screening and Brief Intervention Protocols in Primary Care Settings	Phase 3
Completed	`NCT01481428` - Reducing High Risk Behavior in Treatment Court	Phase 1
Completed	`NCT01601743` - Exercise as a Behavioral Treatment for Cocaine Dependence	N/A
Completed	`NCT01591239` - Home-Based Program to Help Parents of Drug Abusing Adolescents	N/A
Active, not recruiting	`NCT00847548` - Treatment of Intimate Partner Violence and Substance Abuse in a Forensic Setting	N/A
Completed	`NCT01614015` - Building Outcomes With Observation-Based Supervision: An FFT Effectiveness Trial	Phase 2
Withdrawn	`NCT01228890` - Primary Care Internet-Based Depression Prevention for Adolescents (CATCH-IT)	Phase 3
Completed	`NCT01621334` - The Men's Domestic Abuse Check-Up Engages Adult Men Concerned About Their Abusive Behavior and Alcohol or Drug Use	Phase 1
Completed	`NCT00717444` - Healthy Activities for Prize Incentives	N/A
Completed	`NCT00841711` - Transitions: Linkages From Jail To Community	N/A
Completed	`NCT01465490` - Monitoring and Feedback in Substance Abuse Treatment	Phase 1/Phase 2
Completed	`NCT00685074` - Computer-based Brief Intervention for Perinatal Substance Abuse	Phase 1/Phase 2
Completed	`NCT01188434` - Integrating Interventions for Maternal Substance Abuse	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.